Lymphoma Clinical Trials in Austin

Showing 381-391 of 391 trials

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

NCT00955786

This phase 1 study of CX-3543 is designed to test the safety, tolerability and highest safe dose level of this drug in patients with advanced solid tumor cancers.

Advanced Solid TumorsLymphoma

Cylene Pharmaceuticals48 participantsStarted Jul 2005

Scottsdale, Arizona, United States • San Antonio, Texas, United States

COMPLETEDPhase 274 miles

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

NCT00061672

The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.

Lymphoma, Non-HodgkinHodgkin's Lymphoma

Abbott67 participantsStarted Apr 2003

Phoenix, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +11 more locations

UNKNOWNPhase 174 miles

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00090727

The purposes of this study are to determine: * the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle * the side effects of AQ4N when given on the above schedule * how much AQ4N is in the blood and urine at specific times after administration and how the body get rids of AQ4N * if AQ4N helps treat cancer

Solid MalignanciesNon-Hodgkin's Lymphoma

Novacea45 participantsStarted Aug 2004

The Bronx, New York, United States • San Antonio, Texas, United States

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Lymphoma Trials in Other Cities

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Other Conditions in Austin